BriaCell Therapeutics Corp.

Join the Mission at BriaCell! We’re on a journey to change cancer treatment, and we need passionate, curious, and driven people to help us get there. Your ideas, your impact, your future—start here. briacell.com/careers/

We’re hiring! BriaCell Therapeutics is looking for a Part-Time Head of Human Resources (Biotech) to join our growing team. 📍 Remote (U.S.) | Preferred: Philadelphia, PA area 🕒 10–20 hours per week 💼 Reports to CFO Candidates must be authorized to work in the U.S. under any employer. If you’re an experienced HR leader with biotech expertise and looking for a flexible, high-impact role, we’d love to hear from you. Apply or share with your network! briacell.com/careers/

Now Hiring: Oncology CRA / Recruitment Specialist (Hybrid/Remote – U.S.) Are you a Clinical Research Coordinator (CRC) or a newly transitioned Clinical Research Associate (CRA) with oncology experience? Ready to take the next step in your career? We want to hear from you! 🔬 Role: Oncology CRA / Recruitment Specialist 📍 Location: Hybrid/Remote (U.S.-based with travel required) ✈️ Travel: Weekly, based on study needs 📌 Eligibility: Must be authorized to work in the U.S. under any employer We’re looking for a flexible, driven clinical research professional with a clinical degree (or foreign equivalent) to join a dynamic Clinical Operations team supporting oncology trials. Ready to apply? Visit: briacell.com/careers/

We’re Hiring at Briacell Therapeutics! BriaCell is on a mission to transform cancer therapy, and we need talented individuals who are excited to help shape the future of biotech. Come work alongside a dedicated team where your ideas and impact truly matter. See our open roles here: bit.ly/478ecPX

We’re hiring! BriaCell Therapeutics is looking for a Part-Time Head of Human Resources (Biotech) to join our growing team. 📍 Remote (U.S.) | Preferred: Philadelphia, PA area 🕒 10–20 hours per week 💼 Reports to CFO Candidates must be authorized to work in the U.S. under any employer. If you’re an experienced HR leader with biotech expertise and looking for a flexible, high-impact role, we’d love to hear from you. Apply or share with your network! bit.ly/478ecPX

Join the BriaCell Team! BriaCell Therapeutics is expanding, and we’re looking for enthusiastic, driven professionals ready to make a difference in cancer treatment. If you’re passionate about biotech innovation and thrive in a collaborative environment, we want to hear from you! Explore our current opportunities here: bit.ly/478ecPX

BriaCell President and CEO, Dr. William V. Williams, shares his thoughts on the Company’s four poster presentations at the upcoming 2026 American Association for Cancer Research (@AACR) Annual Meeting taking place from April 17th – 22nd. Discover more: bit.ly/4uAQJkl #AACR26 $BCTX $BCTXL

BriaCell is hiring! Briacell Therapeutics is expanding our team and looking for passionate, driven individuals to join us in advancing innovative cancer treatments. If you’re ready to make a meaningful impact in biotech and work alongside a dedicated team, we’d love to hear from you. Explore our open roles and take the next step in your career today. briacell.com/careers/

BriaCell will present four posters at the 2026 American Association for Cancer Research (@AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, two posters highlighting further analyses of Phase 2 data, and one poster presenting preclinical data related to Bria-OTS+, BriaCell’s next-generation personalized off-the-shelf immunotherapy for cancer. Find details: bit.ly/4uAQJkl #AACR26 $BCTX $BCTXL

BriaCell is Hiring: Scientist / Senior Scientist – Quality Control (Philadelphia, PA) Join BriaCell and contribute to the development, qualification, and execution of analytical assays used to characterize cell-based immunotherapies and support research, development, and manufacturing programs! 📍 Location: Philadelphia, PA 💼 Department: Research & Development ✅ Must be authorized to work in the US under any employer Apply now and see all details: briacell.com/careers/

ICYMI: BriaCell announced that four abstracts have been accepted for poster presentation at the @AACR Annual Meeting, taking place April 17th - 22nd. The accepted abstracts highlight research related to BriaCell’s cellular #immunotherapy platform, including the Company’s ongoing pivotal Phase 3 study of Bria-IMT™ in combination with an immune checkpoint inhibitor and research supporting Bria-OTS+™, BriaCell’s next-generation personalized off-the-shelf immunotherapy program. Learn more: bit.ly/4uqVJZ4 #AACR26 $BCTX $BCTXL

BriaCell announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (@AACR) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA. For additional information, please visit: bit.ly/4uqVJZ4 #AACR26 $BCTX $BCTXL

#ICYMI: The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study in #metastaticbreastcancer without modifications. Learn more: bit.ly/4aoDATy $BCTX $BCTXW $BCTXZ $BCTXL

President and CEO Dr. William V. Williams shares insights into BriaCell and BriaPro’s asset purchase agreement for an exclusive soluble CD80 license. Learn more: bit.ly/3MxcYGY $BCTX $BCTXW $BCTXZ $BCTXL

BriaCell and BriaPro announced that they have entered into a definitive purchase agreement pursuant to which BriaPro has agreed to purchase BriaCell’s exclusive license to develop and commercialize Soluble CD80 as a biologic agent for the treatment of cancer and other associated assets. Find details: bit.ly/3MxcYGY $BCTX $BCTXW $BCTXZ $BCTXL

BriaCell President and CEO Dr. William V. Williams commented on the fifth consecutive positive recommendation from Data Safety Monitoring Board (DSMB) for BriaCell's Phase 3 study in #metastaticbreastcancer. Learn more: bit.ly/4aoDATy $BCTX $BCTXW $BCTXZ $BCTXL

BriaCell announced that the independent Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (#CPI) in patients with #metastaticbreastcancer. Find details: bit.ly/4aoDATy $BCTX $BCTXW $BCTXZ $BCTXL

BriaCell's Phase 3 Bria-IMT™ clinical trial in #metastaticbreastcancer has been prominently and independently featured in the @NatureMedicine Year In Review’s publication, “Eleven clinical trials that will shape medicine in 2026”. Read the full article: bit.ly/3CgzknU $BCTX $BCTXW $BCTXZ $BCTXL

On #WorldCancerDay, we stand with patients, families, researchers, and advocates around the globe working toward a future beyond cancer. At BriaCell, we are a clinical stage immuno-oncology company that is developing an entirely new class of targeted #immunotherapies to transform cancer care. Discover how you can get involved: worldcancerday.org #UnitedByUnique #CancerResearch #BreastCancer #MetastaticBreastCancer

ICYMI: BriaCell released new images highlighting resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvement. Discover more: bit.ly/3LE1EZd $BCTX $BCTXW $BCTXZ $BCTXL